From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262411982 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Thelvia I Ramos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Sanidad Animal y Humana (GISAH), Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas E…. Hauptthemen laut MEDLINE: Genetic Engineering, Interferon alpha-2, Interferon-gamma. Die Arbeit nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de las Fuerzas Armadas ESPE, Agencia Nacional de Investigación y Desarrollo, Agencia Nacional de Investigación y Desarrollo (ANID-Chile): Fondecyt Postdoctoral.
Abstract (Originalsprache)
There is a critical gap in the preclinical research of recombinant human interferons (rhIFNα-2b and rhIFN-γ), as most studies focus on modified variants, which complicates the understanding of the native molecules’ properties. This study addresses this limitation by comprehensively evaluating the structural stability and intrinsic toxicity of purified IFNs. Our findings confirm that both interferons retain their bioactivity (antiviral, antiproliferative, and immunomodulatory) and exhibit remarkable stability under controlled conditions. Accelerated stability assays showed that neither protein lost biological potency after 18 days at various temperatures, supporting their potential as liquid formulations. Acute and sub-chronic toxicity studies in rodent, non-rodent, and higher-organism animal models showed no signs of toxicity, even at doses 100 to 300 times higher than therapeutic levels. These assays, combined with the absence of pyrogens, support a favorable safety profile for clinical use, with no evidence of systemic or structural damage. This work establishes a reproducible experimental model and lays the groundwork for future preclinical evaluations. We underscore the importance of characterizing the safety profile of active pharmaceutical ingredients from the earliest stages of biopharmaceutical development to ensure a safe and well-founded transition to human clinical trials. Furthermore, these results open the door for the development of advanced formulations and alternative routes of administration, such as the intranasal route, an area with significant potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Investigación en Sanidad Animal y Humana (GISAH), Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas ESPE, Sangolquí 171103, Ecuador.
- Biotechnology and Biopharmaceutical Laboratory, Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Víctor Lamas 1290, P.O. Box 160-C, Concepción 4030000, Chile.
- Carrera Ingeniería en Biotecnología, Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas-ESPE, Sangolquí 171103, Ecuador.
- Laboratory of Recombinant Biopharmaceuticals, Departamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, Víctor Lamas 1290, P.O. Box 160-C, Concepción 4030000, Chile.
- Clinical Sciences Department, Faculty of Veterinary Sciences, Universidad de Concepción, Vicente Méndez 595, Chillán 3780000, Chile.
- Clinical Biotec, 28029 Madrid, Spain.
ORCID-Profile: Thelvia I Ramos, Carlos A Villacis-Aguirre, Emilio Lamazares, Viana Manrique-Suárez, Felipe Sandoval, Cristy N Culqui-Tapia, Sarah Martin-Solano, Ignacio Cabezas, Oliberto Sánchez, Sergio Donoso-Erch, Natalie C Parra, María A Contreras, Nelson Santiago-Vispo
Förderung
- Universidad de las Fuerzas Armadas ESPE
- Agencia Nacional de Investigación y Desarrollo
- Agencia Nacional de Investigación y Desarrollo (ANID-Chile): Fondecyt Postdoctoral
- Research Management Unit (UGI) from Universidad de las Fuerzas Armadas ESPE
Zitieren
APA
Ramos, T. I., Villacis-Aguirre, C. A., Lamazares, E., Manrique-Suárez, V., Sandoval, F., Culqui-Tapia, C. N., Martin-Solano, S., Mansilla, R., Cabezas, I., Sánchez, O., Donoso-Erch, S., Parra, N. C., Contreras, M. A., & Santiago-Vispo, N. (2025). From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411982
Vancouver
Ramos TI, Villacis-Aguirre CA, Lamazares E, Manrique-Suárez V, Sandoval F, Culqui-Tapia CN, et al. From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411982
BibTeX
@article{Ramos2025,
author = {Ramos, Thelvia I and Villacis-Aguirre, Carlos A and Lamazares, Emilio and Manrique-Suárez, Viana and Sandoval, Felipe and Culqui-Tapia, Cristy N and Martin-Solano, Sarah and Mansilla, Rodrigo and Cabezas, Ignacio and Sánchez, Oliberto and Donoso-Erch, Sergio and Parra, Natalie C and Contreras, María A and Santiago-Vispo, Nelson},
title = {From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262411982}
}
EUVIMED